CA2666686A1 - Inhibitors of 5-lipoxygenase activating protein (flap) - Google Patents

Inhibitors of 5-lipoxygenase activating protein (flap) Download PDF

Info

Publication number
CA2666686A1
CA2666686A1 CA002666686A CA2666686A CA2666686A1 CA 2666686 A1 CA2666686 A1 CA 2666686A1 CA 002666686 A CA002666686 A CA 002666686A CA 2666686 A CA2666686 A CA 2666686A CA 2666686 A1 CA2666686 A1 CA 2666686A1
Authority
CA
Canada
Prior art keywords
optionally substituted
group
4alkyl
pyridin
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002666686A
Other languages
English (en)
French (fr)
Inventor
Anthony Ogawa
Feroze Ujjainwalla
Ellen K. Vande Bunte
Lin Chu
Debra Ondeyka
Ihor Kopka
Bing Li
Hyun Ok
Minal J. Patel
Jinyou Xu
Rosemary Sisco
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2666686A1 publication Critical patent/CA2666686A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
CA002666686A 2006-09-01 2007-08-29 Inhibitors of 5-lipoxygenase activating protein (flap) Abandoned CA2666686A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US84175806P 2006-09-01 2006-09-01
US60/841,758 2006-09-01
US93388607P 2007-06-08 2007-06-08
US60/933,886 2007-06-08
US96159807P 2007-07-23 2007-07-23
US60/961,598 2007-07-23
PCT/US2007/018991 WO2008030369A1 (en) 2006-09-01 2007-08-29 Inhibitors of 5 -lipoxygenase activating protein ( flap)

Publications (1)

Publication Number Publication Date
CA2666686A1 true CA2666686A1 (en) 2008-03-13

Family

ID=38925607

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002666686A Abandoned CA2666686A1 (en) 2006-09-01 2007-08-29 Inhibitors of 5-lipoxygenase activating protein (flap)

Country Status (7)

Country Link
US (1) US8440672B2 (https=)
EP (1) EP2064204B1 (https=)
JP (1) JP2010502615A (https=)
AT (1) ATE543810T1 (https=)
AU (1) AU2007293373A1 (https=)
CA (1) CA2666686A1 (https=)
WO (1) WO2008030369A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007120574A2 (en) 2006-04-11 2007-10-25 Merck & Co., Inc. Diaryl substituted alkanes
ATE543810T1 (de) 2006-09-01 2012-02-15 Merck Sharp & Dohme Hemmer des 5-lipoxygenase aktivierenden proteins (flap)
EP2546232A1 (en) * 2007-06-20 2013-01-16 Merck Sharp & Dohme Corp. Diphenyl Substituted Alkanes
WO2010027762A1 (en) 2008-09-04 2010-03-11 Boehringer Ingelheim International Gmbh Indolizine inhibitors of leukotriene production
WO2010032874A1 (ja) * 2008-09-19 2010-03-25 住友化学株式会社 農業用組成物
JP5690839B2 (ja) 2009-12-04 2015-03-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン産生のベンゾイミダゾール阻害薬
CA2797719C (en) 2010-04-30 2019-11-26 Dana-Farber Cancer Institute, Inc. Small molecule inhibitors of usp1 deubiquitinating enzyme activity
MX2013001872A (es) * 2010-08-16 2013-09-02 Boehringer Ingelheim Int Inhibidores de oxadiazol de la produccion de leucotrieno.
US8580829B2 (en) 2010-08-26 2013-11-12 Boehringer Ingelheim International Gmbh Oxadiazole inhibitors of leukotriene production
PH12013500545A1 (en) * 2010-09-23 2013-05-06 Boehringer Ingelheim Int Oxadiazole inhibitors of leukotriene production
WO2012040137A1 (en) * 2010-09-23 2012-03-29 Boehringer Ingelheim International Gmbh Oxadiazole inhibitors of leukotriene production
EP2632915B1 (en) 2010-10-29 2015-08-12 Boehringer Ingelheim International GmbH Benzimidazole inhibitors of leukotriene production
JP5789888B2 (ja) 2010-11-01 2015-10-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン生成のベンゾイミダゾールインヒビター
US9073895B2 (en) 2010-12-16 2015-07-07 Boehringer Ingelheim International Gmbh Biarylamide inhibitors of leukotriene production
WO2013116182A1 (en) * 2012-01-31 2013-08-08 Boehringer Ingelheim International Gmbh Heterocyclic compounds as inhibitors of leukotriene production
AR089853A1 (es) 2012-02-01 2014-09-24 Boehringer Ingelheim Int Inhibidores de oxadiazol de la produccion de leucotrienos para terapia de combinacion, composicion farmaceutica, uso
EP2865756A1 (en) 2013-10-22 2015-04-29 Sylentis, S.A.U. siRNA and their use in methods and compositions for inhibiting the expression of the FLAP gene.
US9725425B1 (en) 2014-02-25 2017-08-08 Dana-Farber Cancer Institute, Inc. Compounds and methods for treating cancer
WO2016065584A1 (en) 2014-10-30 2016-05-06 Merck Sharp & Dohme Corp. Piperidine oxadiazole and thiadiazole orexin receptor antagonists
US10500178B2 (en) 2015-03-13 2019-12-10 The Board Of Trustees Of The Leland Stanford Junior University LTB4 inhibition to prevent and treat human lymphedema

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU186654B (en) 1982-12-28 1985-09-30 Richter Gedeon Vegyeszet Process for producing new pyridine derivatives, acid additional salts and quaternary salts and pharmaceutical compositions containing them
US4853398A (en) 1987-04-13 1989-08-01 Eli Lilly And Company Leukotriene antagonists and use thereas
US6051573A (en) 1994-06-28 2000-04-18 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with non-steroidal glucocorticoid antagonists
US5795900A (en) 1995-10-03 1998-08-18 Abbott Laboratories Symmetrical bis-heteroaryl-methoxy-phenylalkyl carboxylates as inhibitors of leukotriene biosynthesis
US5668146A (en) 1995-10-03 1997-09-16 Abbott Laboratories Symmetrical bis-heteroarylmethoxyphenyliminoxyalkyl carboxylates as inhibitors of leukotriene biosynthesis
KR20010071908A (ko) 1998-07-15 2001-07-31 스티븐 비. 데이비스 케톤의 입체 선택적인 환원적 아민화
US6468781B1 (en) 1999-07-08 2002-10-22 Bristol-Myers Squibb Company Stereoselective reductive amination of ketones
AU764005B2 (en) 1999-02-25 2003-08-07 Merck Frosst Canada & Co. PDE IV inhibiting compounds, compositions and methods of treatment
DE60128581T2 (de) 2000-10-17 2008-02-14 Excelsyn Molecular Develpopment Ltd., Holywell Herstellung von alpha -hydroxy-carboxy säure mit hilfe von einem gekoppelten enzym system
DE10112401A1 (de) 2001-03-13 2002-09-19 Degussa Alkohol-Dehydrogenase und deren Verwendung
CN1500239A (zh) 2001-03-26 2004-05-26 ��ʽ������Ϣ���� 多媒体日历系统
BRPI0411514A (pt) 2003-06-20 2006-08-01 Coley Pharm Gmbh antagonistas de receptor toll-like de molécula pequena
WO2005009951A2 (en) 2003-07-24 2005-02-03 Merck & Co., Inc. Diphenyl substituted cycloalkanes, compositions containing such compounds and methods of use
JP2007530696A (ja) 2004-03-30 2007-11-01 メルク　エンド　カムパニー　インコーポレーテッド アスパラギン酸プロテアーゼ阻害剤として有用な２−アミノチアゾール化合物
WO2006044602A2 (en) 2004-10-18 2006-04-27 Merck & Co., Inc. Diphenyl substituted alkanes as flap inhiibitors
WO2006098912A1 (en) 2005-03-09 2006-09-21 Merck & Co., Inc. Diphenyl substituted cycloalkanes, compositions containing such compounds and methods of use
UY29610A1 (es) * 2005-06-21 2007-01-31 Cancer Rec Tech Ltd Aril-alquilaminas y heteroaril-alquilaminas como inhibidores de la quinasa proteínica
JPWO2007013694A1 (ja) 2005-07-29 2009-02-12 武田薬品工業株式会社 フェノキシアルカン酸化合物
US20090258885A1 (en) 2005-11-04 2009-10-15 Armstrong Helen M Diphenylmethane Derivatives as Inhibitors of Leukotriene Biosynthesis
WO2007120574A2 (en) 2006-04-11 2007-10-25 Merck & Co., Inc. Diaryl substituted alkanes
ATE543810T1 (de) 2006-09-01 2012-02-15 Merck Sharp & Dohme Hemmer des 5-lipoxygenase aktivierenden proteins (flap)
EP2546232A1 (en) 2007-06-20 2013-01-16 Merck Sharp & Dohme Corp. Diphenyl Substituted Alkanes
AU2008311375A1 (en) 2007-10-10 2009-04-16 Merck Sharp & Dohme Corp. Diphenyl substituted cycloalkanes
AU2009217518A1 (en) 2008-02-28 2009-09-03 Merck Sharp & Dohme Corp. 2-aminoimidazole beta-secretase inhibitors for the treatment of Alzheimer's disease

Also Published As

Publication number Publication date
WO2008030369A1 (en) 2008-03-13
US8440672B2 (en) 2013-05-14
ATE543810T1 (de) 2012-02-15
EP2064204B1 (en) 2012-02-01
US20100168076A1 (en) 2010-07-01
EP2064204A1 (en) 2009-06-03
AU2007293373A1 (en) 2008-03-13
JP2010502615A (ja) 2010-01-28

Similar Documents

Publication Publication Date Title
CA2666686A1 (en) Inhibitors of 5-lipoxygenase activating protein (flap)
US8124628B2 (en) Diaryl substituted alkanes
US20100190761A1 (en) Diphenyl substituted alkanes
CA2702225A1 (en) Diphenyl substituted cycloalkanes
EP2375904B1 (en) Biaryl carboxamides
US20090197883A1 (en) Diphenyl Substituted Cycloalkanes, Compositions Containing Such Compounds and Methods Of Use
WO2006044602A2 (en) Diphenyl substituted alkanes as flap inhiibitors
WO2005009951A2 (en) Diphenyl substituted cycloalkanes, compositions containing such compounds and methods of use
WO2007056210A2 (en) Diphenylmethane derivatives as inhibitors of leukotriene biosynthesis

Legal Events

Date Code Title Description
FZDE Discontinued